Tenax Therapeutics is trading at $1.42, down 6.29%, amid biotech and broader-market weakness.
- The XBI is down 2.06%.
- No new company-specific announcement explaining the October 16 decline surfaced in the search. The LEVEL-2 enrollment pause announced October 8 followed a prior Phase 3 trial miss; it is not a new catalyst today.
- Sphera’s reported stake increase is dated October 15 and does not clearly explain the decline.